Collaboration - August 24, 2015
AZ, Peregrine to collaborate
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals. The companies will evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in […]
New Market - June 8, 2015
AZ’s Interest in Immuno-oncology Grows
AstraZeneca and Medimmune, AstraZeneca PLC’s global biologics research and development unit, gave a presentation on the company’s pipeline in the area of immuno-oncology at the recent American Society of Clinical Oncology meeting. Immuno-oncology involves programming or stimulating the body’s own immune system to attack cancer cells, according to BioSpace.com. The companies reported on a number of pipeline […]
